Variantes genéticas del SARS-CoV-2 y sus implicaciones clínicas
Palabras clave:
coronavirus, SARS-CoV-2, COVID-19, mutación, farmacorresistencia viral.Resumen
El SARS-CoV-2, agente causal de la actual pandemia de la COVID-19, va sufriendo mutaciones como consecuencia de su ciclo evolutivo, lo que ha originado diferentes variantes genéticas, que han sido agrupadas en dos categorías: preocupante (alfa o británica, beta o sudafricana, gamma o brasileña y delta o india) y de interés (lamdba, mu, épsilon, eta, iota, kappa, zeta, theta); estas conllevan implicaciones clínicas en la transmisibilidad, virulencia y resistencia del SARS-CoV-2 a la inmunidad natural y adquirida, lo que representa un serio desafío para los servicios de salud en todo el mundo. En este artículo se describen dichas variantes genéticas, con énfasis en su probable impacto clínico, y además se plantea la posibilidad de que aparezcan otras, como fenómeno natural en la evolución de los virus.
Descargas
Los datos de descargas todavía no están disponibles.
Citas
1. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020 [citado 10/09/2021];10:587269. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723891
2. Chadha J, Khullar L, Mittal N. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease‐19 pandemic. Environ Microbiol. 2021 [citado 10/08/2021]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441773/pdf/EMI-9999-0.pdf
3. Joshi M, Puvar A, Kumar D, Ansari A, Pandya M, Raval J, et al. Genomic Variations in SARS-CoV-2 Genomes From Gujarat: Underlying Role of Variants in Disease Epidemiology. Front Genet. 2021 [citado 10/08/2021];12:586569. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017293
4. Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact inGlobal Vaccination Programs againstSARS-CoV-2/COVID-19. Vaccines. 2021 [citado 10/08/2021];9(3):243. Disponible en: https://www.mdpi.com/2076-393X/9/3/243/pdf
5. Seyed Alinaghi SA, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res. 2021 [citado 10/08/2021];26(1):51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185313
6. Kantor IN, Luthy IA, Ritacco GV. Las variantes de SARS-CoV-2 y la llamada resistencia a las vacunas. Medicina (Buenos Aires). 2021 [citado 10/08/2021];81:421-6. Disponible en: https://ri.conicet.gov.ar/bitstream/handle/11336/139805/CONICET_Digital_Nro.73fb5b93-8455-44e3-aea0-f2e12c5872c8_A.pdf?sequence=2&isAllowed=y
7. Pérez-Abeledo M, Sanz Moreno JC. Variantes de SARS-CoV-2, una historia todavía inacabada. Vacunas. 2021 [citado 10/08/2021];22(3):173-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S2445146021000406/pdfft?md5=ec776c9a68f326ae84d245302643db73&pid=1-s2.0-S2445146021000406-main.pdf
8. Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021 [citado 10/08/2021];54(7):1611–21. Disponible en: https://www.sciencedirect.com/science/article/pii/S1074761321002478/pdfft?md5=b54b25fb60378ed257dcdf1112249413&pid=1-s2.0-S1074761321002478-main.pdf
9. Fang S, Li K, Shen J, Liu S, Liu J, Yang L, et al. GESS: a database of global evaluation of /hCoV-19 sequences. Nucleic Acids Research. 2021 [citado 12/08/2021];49(D1): D706–D714. Disponible en: https://academic.oup.com/nar/article/49/D1/D706/5921286
10. World Health Organization. Tracking SARS-CoV-2 variants. Ginebra: WHO; 2021 [citado 12/08/2021]. Disponible en: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
11. McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021 [citado 12/08/2021];373:648-54. Disponible en: https://www.science.org/doi/epdf/10.1126/science.abi7994
12. Resende PC, Delatorre E, Gräf T, Mir D, Coutto Motta F, Reiss Appolinario L, et al. Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 Lineage B.1.1.33 during the early pandemic phase in Brazil. Front Microbiol. 2021 [citado 10/08/2021];11:615280. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925893/pdf/fmicb-11-615280.pdf
13. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021 Sep [citado 10/08/2021]. Disponible en: https://www.nature.com/articles/s41576-021-00408-x.pdf
14. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee S-S. Evolution, mode of transmission, andmutational landscape of newly emerging SARS-CoV-2 variants. mBio. 2021 [citado 10/08/2021];12:e01140-21. Disponible en: https://journals.asm.org/doi/full/10.1128/mBio.01140-21
15. Renostro Delai R, Ramathan Freitas A, Welker Biondo A. Variantes genéticas del SARS-CoV-2. Revista Clínica Veterinaria. 2021 [citado 10/08/2021];26(152). Disponible en: https://www.revistaclinicaveterinaria.com/science/edicion-152/variantes-geneticas-del-sars-cov-2/
16. Vilar S, Isom DG. One Year of SARS-CoV-2: How Much Has the Virus Changed? Biology. 2021 [citado 10/08/2021];10(2):91. Disponible en: https://www.mdpi.com/2079-7737/10/2/91/htm
17. Pandey U, Yee R, Shen L, Judkins AR, Bootwalla M, Ryutov A, et al. High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19. Open Forum Infectious Diseases. 2021 [citado 10/08/2021];8(6):551. Disponible en: https://academic.oup.com/ofid/article/8/6/ofaa551/5981353
18. Zhu Z, Liu G, Meng K, Yang L, Liu D, Meng G, Rapid Spread of Mutant Alleles in Worldwide SARS-CoV-2 Strains Revealed by Genome-Wide Single Nucleotide Polymorphism and Variation Analysis, Genome Biology and Evolution. 2021 [citado 10/08/2021];13(2). Disponible en: https://academic.oup.com/gbe/article/13/2/evab015/6123746
19. Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules. 2021 [citado 10/08/2021];11(7):993. Disponible en: https://www.mdpi.com/2218-273X/11/7/993/pdf
20. Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotan K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020 [citado 10/08/2021];65:1075-82. Disponible en: https://www.nature.com/articles/s10038-020-0808-9.pdf
21. Antony P, Vijayan R. Role of SARS-CoV-2 and ACE2 variations in COVID-19. Biomed J. 2021 [citado 10/08/2021];44(3):235-44. Disponible en: https://www.sciencedirect.com/science/article/pii/S2319417021000366/pdfft?md5=cda398ab8200f8bf36e3bad92e2f3b48&pid=1-s2.0-S2319417021000366-main.pdf
22. Desimmie BA, Raru, YY, Awadh HM, He P, Teka S, Willenburg, KS. Insights intoSARS-CoV-2 Persistence and Its Relevance. Viruses. 2021 [citado 10/09/2021];13(6):1025. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34072390/
23. Pohl MO, Busnadiego I, Kufner V, Glas I, Karakus U, Schmutz S, et al. SARS-CoV-2 variants reveal features critical for replication in primary human cells. PLoS Biol. 2021 [citado 10/08/2021];19(3):3001006. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021179/
24. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U.S.A. 2020 [citado 10/08/2021];117(21):11727-34. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260975/
25. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 [citado 10/08/2021];52(4):583-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S1074761320301205/pdfft?md5=0afe6c765f14b8bbc390f2b80f3301d0&pid=1-s2.0-S1074761320301205-main.pdf
26. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 [citado 10/08/2021];586:516–27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260975/
27. Scheid JF, Barnes CO, Eraslan B, Hudak A, Keeffe JR, Cosimi LA, et al. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell. 2021 [citado 10/08/2021];184(12):3205–21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064835/
28. Puray-Chavez M, LaPak KM, Schrank TP, Elliott JL, Bhatt DP, Agajanian MJ, et al. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Rep. 2021 [citado 10/08/2021];36(2):109364. Disponible en: https://www.sciencedirect.com/science/article/pii/S2211124721007622/pdfft?md5=e6eaaa47f96d8cef1e0fa50051f9a8c1&pid=1-s2.0-S2211124721007622-main.pdf
29. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. 2021[citado 10/08/2021];325(13):1318–20. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2777059
30. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews. 2021 [citado 10/08/2021];19:141-54. Disponible en: https://www.nature.com/articles/s41579-020-00459-7.pdf
31. Colson P, Devaux CA, Lagier JC, Gautret P, Raoult D. A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. J Clin Med. 2021 [citado 10/08/2021];10(15):3276. Disponible en: https://www.mdpi.com/2077-0383/10/15/3276/pdf
32. Fantini J, Yahi N, Azzaz F, Chahinian H. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks. J Infect. 2021 [citado 10/08/2021];83(2):197-206. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172274/
33. Silva-Ayarza I, Bachelet VC. Lo que sabemos y no sabemos sobre SARS-CoV-2 y COVID-19. Medwave. 2021 [citado 10/08/2021];21(4):8198. Disponible en: https://www.medwave.cl/link.cgi/Medwave/Revisiones/RevisionClinica/8198.act
34. Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis. 2021 [citado 10/08/2021];25(4):101606. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367756/
35. Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinical Medicine. 2021 [citado 10/08/2021];40:101129. Disponible en: https://www.thelancet.com/action/showPdf?pii=S2589-5370%2821%2900409-0
36. Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 [citado 10/08/2021];596(7871):268–72. Disponible en: https://www.nature.com/articles/s41586-021-03681-2
37. Tostanoski LH, Yu J, Mercado NB, McMahan K, Jacob-Dolan C, Martinot AJ, et al. Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Sci Transl Med. 2021 [citado 10/08/2021];13(618). Disponible en: https://www.science.org/doi/10.1126/scitranslmed.abj3789
38. Abdelnabi R, Boudewijns R, Foo CS, Seldeslachts L, Sanchez-Felipe L, Zhang X, et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine. 2021 [citado 10/08/2021];68:103403. Disponible en: https://www.thelancet.com/action/showPdf?pii=S2352-3964%2821%2900196-1
39. Wu J, Zhang L, Zhang Y, Wang H, Ding R, Nie J, et al. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021 [citado 10/08/2021];12:687869. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247764/pdf/fimmu-12-687869.pdf
40. Kaku Y, Kuwata T, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, et al. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep. 2021 [citado 10/08/2021];36(2):109385. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226103/
41. Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Rep. 2021 [citado 10/08/2021];36(11):109708. Disponible en: https://www.sciencedirect.com/science/article/pii/S2211124721011554/pdfft?md5=220064ff6fedd3ca23b3546a9c79d37a&pid=1-s2.0-S2211124721011554-main.pdf
42. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021 [citado 10/08/2021];184(9):2384–93. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980144/
43. Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res. 2021 [citado 10/08/2021];13(6):317-25. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256910/
2. Chadha J, Khullar L, Mittal N. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease‐19 pandemic. Environ Microbiol. 2021 [citado 10/08/2021]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441773/pdf/EMI-9999-0.pdf
3. Joshi M, Puvar A, Kumar D, Ansari A, Pandya M, Raval J, et al. Genomic Variations in SARS-CoV-2 Genomes From Gujarat: Underlying Role of Variants in Disease Epidemiology. Front Genet. 2021 [citado 10/08/2021];12:586569. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017293
4. Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact inGlobal Vaccination Programs againstSARS-CoV-2/COVID-19. Vaccines. 2021 [citado 10/08/2021];9(3):243. Disponible en: https://www.mdpi.com/2076-393X/9/3/243/pdf
5. Seyed Alinaghi SA, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res. 2021 [citado 10/08/2021];26(1):51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185313
6. Kantor IN, Luthy IA, Ritacco GV. Las variantes de SARS-CoV-2 y la llamada resistencia a las vacunas. Medicina (Buenos Aires). 2021 [citado 10/08/2021];81:421-6. Disponible en: https://ri.conicet.gov.ar/bitstream/handle/11336/139805/CONICET_Digital_Nro.73fb5b93-8455-44e3-aea0-f2e12c5872c8_A.pdf?sequence=2&isAllowed=y
7. Pérez-Abeledo M, Sanz Moreno JC. Variantes de SARS-CoV-2, una historia todavía inacabada. Vacunas. 2021 [citado 10/08/2021];22(3):173-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S2445146021000406/pdfft?md5=ec776c9a68f326ae84d245302643db73&pid=1-s2.0-S2445146021000406-main.pdf
8. Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021 [citado 10/08/2021];54(7):1611–21. Disponible en: https://www.sciencedirect.com/science/article/pii/S1074761321002478/pdfft?md5=b54b25fb60378ed257dcdf1112249413&pid=1-s2.0-S1074761321002478-main.pdf
9. Fang S, Li K, Shen J, Liu S, Liu J, Yang L, et al. GESS: a database of global evaluation of /hCoV-19 sequences. Nucleic Acids Research. 2021 [citado 12/08/2021];49(D1): D706–D714. Disponible en: https://academic.oup.com/nar/article/49/D1/D706/5921286
10. World Health Organization. Tracking SARS-CoV-2 variants. Ginebra: WHO; 2021 [citado 12/08/2021]. Disponible en: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
11. McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science. 2021 [citado 12/08/2021];373:648-54. Disponible en: https://www.science.org/doi/epdf/10.1126/science.abi7994
12. Resende PC, Delatorre E, Gräf T, Mir D, Coutto Motta F, Reiss Appolinario L, et al. Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 Lineage B.1.1.33 during the early pandemic phase in Brazil. Front Microbiol. 2021 [citado 10/08/2021];11:615280. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925893/pdf/fmicb-11-615280.pdf
13. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021 Sep [citado 10/08/2021]. Disponible en: https://www.nature.com/articles/s41576-021-00408-x.pdf
14. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee S-S. Evolution, mode of transmission, andmutational landscape of newly emerging SARS-CoV-2 variants. mBio. 2021 [citado 10/08/2021];12:e01140-21. Disponible en: https://journals.asm.org/doi/full/10.1128/mBio.01140-21
15. Renostro Delai R, Ramathan Freitas A, Welker Biondo A. Variantes genéticas del SARS-CoV-2. Revista Clínica Veterinaria. 2021 [citado 10/08/2021];26(152). Disponible en: https://www.revistaclinicaveterinaria.com/science/edicion-152/variantes-geneticas-del-sars-cov-2/
16. Vilar S, Isom DG. One Year of SARS-CoV-2: How Much Has the Virus Changed? Biology. 2021 [citado 10/08/2021];10(2):91. Disponible en: https://www.mdpi.com/2079-7737/10/2/91/htm
17. Pandey U, Yee R, Shen L, Judkins AR, Bootwalla M, Ryutov A, et al. High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19. Open Forum Infectious Diseases. 2021 [citado 10/08/2021];8(6):551. Disponible en: https://academic.oup.com/ofid/article/8/6/ofaa551/5981353
18. Zhu Z, Liu G, Meng K, Yang L, Liu D, Meng G, Rapid Spread of Mutant Alleles in Worldwide SARS-CoV-2 Strains Revealed by Genome-Wide Single Nucleotide Polymorphism and Variation Analysis, Genome Biology and Evolution. 2021 [citado 10/08/2021];13(2). Disponible en: https://academic.oup.com/gbe/article/13/2/evab015/6123746
19. Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules. 2021 [citado 10/08/2021];11(7):993. Disponible en: https://www.mdpi.com/2218-273X/11/7/993/pdf
20. Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotan K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020 [citado 10/08/2021];65:1075-82. Disponible en: https://www.nature.com/articles/s10038-020-0808-9.pdf
21. Antony P, Vijayan R. Role of SARS-CoV-2 and ACE2 variations in COVID-19. Biomed J. 2021 [citado 10/08/2021];44(3):235-44. Disponible en: https://www.sciencedirect.com/science/article/pii/S2319417021000366/pdfft?md5=cda398ab8200f8bf36e3bad92e2f3b48&pid=1-s2.0-S2319417021000366-main.pdf
22. Desimmie BA, Raru, YY, Awadh HM, He P, Teka S, Willenburg, KS. Insights intoSARS-CoV-2 Persistence and Its Relevance. Viruses. 2021 [citado 10/09/2021];13(6):1025. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34072390/
23. Pohl MO, Busnadiego I, Kufner V, Glas I, Karakus U, Schmutz S, et al. SARS-CoV-2 variants reveal features critical for replication in primary human cells. PLoS Biol. 2021 [citado 10/08/2021];19(3):3001006. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021179/
24. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U.S.A. 2020 [citado 10/08/2021];117(21):11727-34. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260975/
25. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 [citado 10/08/2021];52(4):583-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S1074761320301205/pdfft?md5=0afe6c765f14b8bbc390f2b80f3301d0&pid=1-s2.0-S1074761320301205-main.pdf
26. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 [citado 10/08/2021];586:516–27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260975/
27. Scheid JF, Barnes CO, Eraslan B, Hudak A, Keeffe JR, Cosimi LA, et al. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell. 2021 [citado 10/08/2021];184(12):3205–21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064835/
28. Puray-Chavez M, LaPak KM, Schrank TP, Elliott JL, Bhatt DP, Agajanian MJ, et al. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Rep. 2021 [citado 10/08/2021];36(2):109364. Disponible en: https://www.sciencedirect.com/science/article/pii/S2211124721007622/pdfft?md5=e6eaaa47f96d8cef1e0fa50051f9a8c1&pid=1-s2.0-S2211124721007622-main.pdf
29. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. 2021[citado 10/08/2021];325(13):1318–20. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2777059
30. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews. 2021 [citado 10/08/2021];19:141-54. Disponible en: https://www.nature.com/articles/s41579-020-00459-7.pdf
31. Colson P, Devaux CA, Lagier JC, Gautret P, Raoult D. A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. J Clin Med. 2021 [citado 10/08/2021];10(15):3276. Disponible en: https://www.mdpi.com/2077-0383/10/15/3276/pdf
32. Fantini J, Yahi N, Azzaz F, Chahinian H. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks. J Infect. 2021 [citado 10/08/2021];83(2):197-206. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172274/
33. Silva-Ayarza I, Bachelet VC. Lo que sabemos y no sabemos sobre SARS-CoV-2 y COVID-19. Medwave. 2021 [citado 10/08/2021];21(4):8198. Disponible en: https://www.medwave.cl/link.cgi/Medwave/Revisiones/RevisionClinica/8198.act
34. Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis. 2021 [citado 10/08/2021];25(4):101606. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367756/
35. Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinical Medicine. 2021 [citado 10/08/2021];40:101129. Disponible en: https://www.thelancet.com/action/showPdf?pii=S2589-5370%2821%2900409-0
36. Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021 [citado 10/08/2021];596(7871):268–72. Disponible en: https://www.nature.com/articles/s41586-021-03681-2
37. Tostanoski LH, Yu J, Mercado NB, McMahan K, Jacob-Dolan C, Martinot AJ, et al. Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Sci Transl Med. 2021 [citado 10/08/2021];13(618). Disponible en: https://www.science.org/doi/10.1126/scitranslmed.abj3789
38. Abdelnabi R, Boudewijns R, Foo CS, Seldeslachts L, Sanchez-Felipe L, Zhang X, et al. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine. 2021 [citado 10/08/2021];68:103403. Disponible en: https://www.thelancet.com/action/showPdf?pii=S2352-3964%2821%2900196-1
39. Wu J, Zhang L, Zhang Y, Wang H, Ding R, Nie J, et al. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. Front Immunol. 2021 [citado 10/08/2021];12:687869. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247764/pdf/fimmu-12-687869.pdf
40. Kaku Y, Kuwata T, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, et al. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep. 2021 [citado 10/08/2021];36(2):109385. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226103/
41. Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Rep. 2021 [citado 10/08/2021];36(11):109708. Disponible en: https://www.sciencedirect.com/science/article/pii/S2211124721011554/pdfft?md5=220064ff6fedd3ca23b3546a9c79d37a&pid=1-s2.0-S2211124721011554-main.pdf
42. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021 [citado 10/08/2021];184(9):2384–93. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980144/
43. Vasireddy D, Vanaparthy R, Mohan G, Malayala SV, Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res. 2021 [citado 10/08/2021];13(6):317-25. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256910/
Publicado
2021-12-08
Cómo citar
1.
Expósito Lara A, Feria Díaz GE, González Benítez SN, Miguel Soca PE. Variantes genéticas del SARS-CoV-2 y sus implicaciones clínicas. MEDISAN [Internet]. 8 de diciembre de 2021 [citado 1 de junio de 2025];25(6):1424-46. Disponible en: https://medisan.sld.cu/index.php/san/article/view/3878
Número
Sección
Artículo de revisión
Licencia
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al público, apoya aún más el intercambio de conocimiento global. Esto significa que los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento, no comercial de Creative Commons 4.0 internacional que permite la realización de copias y distribución de los contenidos por cualquier medio o formato, siempre que otorgue el crédito apropiado, proporcione un enlace a la licencia e indique si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o a su uso y no puede usar el material con fines comerciales.
![Secimed](/templates/images/secimed.png"){kind=small}
Directrices para autores
